Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

Executive Summary

‘Better informed patients,’ ‘drug competition,’  ‘biosimilar innovation’ as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.


Related Content

Off-Label Communications Bill Allowing Discussion Of Unapproved Drugs Advances
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling
Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says
Opioid Hearing: Senators Want Speed, But Agency Heads Stress Time, Effort
FDA's Opioid Programs: After Training, What's The Next Step?
US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security
Abuse Deterrent Opioids: Which Studies Will Show Real World Effect?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts